ARIXTRA® Adherence in SVT Patients. - Trial NCT01691495
Access comprehensive clinical trial information for NCT01691495 through Pure Global AI's free database. This phase not specified trial is sponsored by GlaxoSmithKline and is currently Completed. The study focuses on Thrombosis, Venous. Target enrollment is 1 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
GlaxoSmithKline
Timeline & Enrollment
N/A
Oct 01, 2012
Aug 01, 2014
Primary Outcome
The primary outcome will be a measure of physician adherence.
Summary
Fondaparinux is an anticoagulant used in the prevention and treatment of thromboembolic
 disease. It has recently been approved in the European Union (EU) for the treatment of
 patients with isolated superficial vein thrombosis (SVT), i.e. without concomitant deep vein
 thrombosis (DVT), of the lower limbs. As part of EU approval, GlaxoSmithKline (GSK) committed
 to evaluate physicians' adherence to fondaparinux prescribing information regarding proper
 diagnosis and dosing for the treatment of SVT.
 
 The primary objective is to evaluate physicians' adherence to fondaparinux prescribing
 information for the treatment of patients with SVT without concomitant DVT.
 
 The study is designed as a non-interventional, retrospective chart review of patients
 prescribed fondaparinux to treat their SVT. The study will be conducted in several EU
 countries.
 
 ARIXTRA® is a registered trademark of the GlaxoSmithKline group of companies.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT01691495
Non-Device Trial